Mayinglong Pharmaceutical Group Co Ltd Capital Reinvestment Ratio
Mayinglong Pharmaceutical Group Co Ltd capital reinvestment ratio. Mayinglong Pharmaceutical Group Co Ltd (600993) has a Capital Reinvestment Ratio of 0.10x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥139.20 Million) in capital expenditures (CN¥13.73 Million). Check Mayinglong Pharmaceutical Group Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Capital reinvestment ratio of Mayinglong Pharmaceutical Group Co Ltd from 2003 to 2025. This chart tracks Mayinglong Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 22 annual periods. Also explore 600993 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Mayinglong Pharmaceutical Group Co Ltd Capital Reinvestment Ratio by Year (2003–2025)
Mayinglong Pharmaceutical Group Co Ltd capital reinvestment ratio by year from 2003 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of Mayinglong Pharmaceutical Group Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥600.44 Million | CN¥119.37 Million | ▼ -51.5% |
| 2024 | 0.41x | CN¥497.61 Million | CN¥203.85 Million | ▼ -0.4% |
| 2023 | 0.41x | CN¥604.07 Million | CN¥248.36 Million | ▲ +87.4% |
| 2022 | 0.22x | CN¥341.85 Million | CN¥75.01 Million | ▲ +101.3% |
| 2021 | 0.11x | CN¥597.17 Million | CN¥65.10 Million | ▼ -32.1% |
| 2020 | 0.16x | CN¥282.99 Million | CN¥45.41 Million | ▲ +70.2% |
| 2019 | 0.09x | CN¥491.58 Million | CN¥46.36 Million | ▲ +16.4% |
| 2018 | 0.08x | CN¥308.24 Million | CN¥24.96 Million | ▼ -31.2% |
| 2017 | 0.12x | CN¥356.17 Million | CN¥41.91 Million | ▼ -56.8% |
| 2016 | 0.27x | CN¥239.60 Million | CN¥65.24 Million | ▼ -59.8% |
| 2015 | 0.68x | CN¥182.85 Million | CN¥123.93 Million | ▼ -29.2% |
| 2014 | 0.96x | CN¥111.67 Million | CN¥106.87 Million | ▲ +48.6% |
| 2013 | 0.64x | CN¥129.94 Million | CN¥83.68 Million | ▲ +232.8% |
| 2012 | 0.19x | CN¥169.25 Million | CN¥32.75 Million | ▼ -67.4% |
| 2011 | 0.59x | CN¥75.37 Million | CN¥44.69 Million | ▲ +266.9% |
| 2009 | 0.16x | CN¥216.11 Million | CN¥34.93 Million | ▼ -49.5% |
| 2008 | 0.32x | CN¥102.59 Million | CN¥32.84 Million | ▼ -91.6% |
| 2007 | 3.80x | CN¥6.49 Million | CN¥24.65 Million | ▲ +1242.0% |
| 2006 | 0.28x | CN¥75.27 Million | CN¥21.32 Million | ▼ -54.0% |
| 2005 | 0.62x | CN¥58.43 Million | CN¥35.95 Million | ▲ +15.2% |
| 2004 | 0.53x | CN¥54.19 Million | CN¥28.94 Million | ▲ +148.1% |
| 2003 | 0.22x | CN¥67.52 Million | CN¥14.54 Million | — |